Jacobs Levy Equity Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,033,763
Closed -$519K 1147
2024
Q4
$519K Buy
+1,033,763
New +$759K ﹤0.01% 810
2023
Q1
Sell
-202,202
Closed -$237K 1019
2022
Q4
$237K Sell
202,202
-55,259
-21% -$69.6K ﹤0.01% 889
2022
Q3
$291K Buy
+257,461
New +$378K ﹤0.01% 891
2018
Q3
Sell
-118,687
Closed -$214K 1035
2018
Q2
$214K Buy
118,687
+38,876
+49% +$78.3K ﹤0.01% 947
2018
Q1
$188K Sell
79,811
-68,819
-46% -$161K ﹤0.01% 937
2017
Q4
$280K Sell
148,630
-13,393
-8% -$29.2K ﹤0.01% 853
2017
Q3
$403K Buy
162,023
+30,568
+23% +$75.8K 0.01% 737
2017
Q2
$362K Buy
+131,455
New +$367K 0.01% 740

Other funds holding LCTX